Aurobindo Pharma Limited Earnings Summary — Q4 FY2026

• Revenue reached a multi-year quarterly high of INR 8,853 Crores, representing 6% YoY growth.
• Profitability remains stable with quarterly Net Profit crossing the INR 920 Crore mark for the first time in this fiscal cycle.
• Operating Profit Margins (OPM) moderated to 20%, down from 21% in Q3 FY26, as expenses grew 3.3% QoQ.
• Depreciation and Interest costs continue to climb, with depreciation hitting INR 479 Crores this quarter.
• The tax rate normalized significantly to 29% for the quarter compared to 32% in the preceding quarter.
• Aurobindo maintains its position as a dominant US generic volume player while transitioning toward complex biologics.

Management is steering 'Aurobindo 2.0' with a focus on complex generics and CDMO services, highlighted by high-profile partnerships like the anchor customer MSD for their new biologics facility.

Stable

Revenue growth is steady, but margin compression and rising fixed costs (depreciation) offset top-line gains.

The outlook hinges on the scale-up of the TheraNym biologics CMO business and managing regulatory scrutiny across US facilities. While revenue is compounding, the company must address high working capital intensity and low ROE.